Table 1.
Patient characteristics (N = 27)
| Characteristic | Value | Percentage/range |
|---|---|---|
| Mean age at EMP Dx, y | 56 y | 42–86 |
| Gender ratio | 18 M: 9 F | |
| Type of EMP | ||
| Primary | 15/27 | 56% |
| Secondary | 12/27 | 44% |
| Involved lymph nodes | ||
| Yes | 7/27 | 26% |
| No | 20/27 | 74% |
| Bone infiltration/erosion | ||
| Yes | 13/27 | 26% |
| No | 20/27 | 74% |
| Immunohistochemical analysis | ||
| Kappa light chain restriction | 11/27 | 41% |
| Lambda light chain restriction | 9/27 | 33% |
| unknown | 7/27 | 26% |
| Serum Beta-2-microglobulin | ||
| Elevated | 5/27 | 18% |
| Normal | 7/27 | 26% |
| Unknown | 15/27 | 56% |
| Serum protein | ||
| Elevated | 3/27 | 11% |
| Normal | 17/27 | 63% |
| Low | 3/27 | 11% |
| Unknown | 4/27 | 15% |
| Serum protein immunofixation | ||
| Positive | 14/27 | 52% |
| Negative | 9/27 | 33% |
| Unknown | 4/27 | 15% |
| Serum LDH | ||
| Elevated | 12/27 | 44% |
| Normal | 11/27 | 41% |
| Unknown | 4/27 | 15% |
| Serum calcium | ||
| Elevated | 1/27 | 4% |
| Normal | 21/27 | 78% |
| Low | 2/27 | 7% |
| Unknown | 3/27 | 11% |
| Prior or adjuvant therapies | ||
| HSCT | 12/27 | 44% |
| TBI | 3/27 | 11% |
| Systemic immunochemotherapy | 14/27 | 52% |
F female, M male, Med. median, LDH lactate dehydrogenase, HSCT Hematopoietic stem cell transplantation, TBI total body irradiation